The identification of causative genetic mutations leading to early-onset AD (APP, PSEN1, PSEN2) and susceptibility markers associated with later disease onset (e.g., APOE ε4 carriers) is crucial to determine specific patterns of cognitive impairment in younger patients with a family history of AD or other neurodegenerative diseases (Rocchi et al., 2003; Winblad et al., 2004; Albert et al., 2011), and to better screen candidates for different stimulation protocols targeting specific neurofunctional mechanisms. Here, APOE is linked to neurodegenerative disease.